NEW YORK, March 5 /PRNewswire-FirstCall/ -- NeoStem, Inc. (Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, today announced that Denis Rodgerson, Ph.D., NeoStem's Director of Stem Cell Science will lecture at The University of Nevada Las Vegas campus this evening. In October 2007, NeoStem announced the expansion of its network of adult stem cell collection centers into Las Vegas, the first in the region.
Dr. Rodgerson's lecture, entitled, "Stem Cells & Regenerative Medicine: Past, Present & Future," will address the evolving nature of stem cell research and applications as well as NeoStem's proprietary Very Small Embryonic Like Stem Cells (VSELs) technology and its potential role in the market.
Dr. Rodgerson has published more than 150 articles in medical and scientific literature and is the holder of several patents. He is an inventor of the proprietary process that serves as the basis for NeoStem's platform stem cell collection business and was the founder of NeoStem's predecessor company. He has been a consultant to many institutions and corporations, including NASA, National Bureau of Standards, Hewlett Packard, and Beckman Instruments. Prior to founding NeoStem, Dr. Rodgerson founded StemCyte, Inc., an umbilical cord blood banking company, where he served as Chief Operating Officer and Senior Vice President until 2002. He is also Professor Emeritus of Pathology and Laboratory Medicine at the UCLA School of Medicine.
About NeoStem, Inc.
NeoStem is managing a growing nationwide network of adult stem cell collection centers, enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also recently entered the research and development and therapeutic arenas, through the acquisition of a worldwide exclusive license to an early-stage technology to identify and isolate rare stem cells from adult human bone marrow, called VSELs (very small embryonic- like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.
Certain statements in this press release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform
Act of 1995, including statements concerning the ability of NeoStem, Inc.
("the Company") to develop the adult stem cell business, to develop the
VSEL technology, the future of regenerative medicine and the role of adult
stem cells and VSELs in that future, the future use of adult stem cells and
VSELs as a treatment option and the potential revenue growth of the
Company's business. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company, or industry results,
to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking statements. The
Company's ability to enter the adult stem cell arena, its success in such
arena and future operating results are dependent upon many factors,
including but not limited to (i) the Company's ability to obtain sufficient
capital or a strategic business arrangements to fund its expansion plans;
(ii) the Company's ability to build the management and human resources and
infrastructure necessary to support the growth of its business; (iii)
competitive factors and developments beyond the Company's control; (iv)
scientific and medical developments beyond the Company's control; (v) the
Company's inability to obtain appropriate state licenses or any other
adverse effect or limitations caused by government regulation of the
business; (vi) whether any of the Company's current or future patent
applications result in issued patents; and (vii) other risk factors
discussed in the Company's periodic filings with the Securities and
Robin Smith, Chief Executive Officer
|SOURCE NeoStem, Inc.|
Copyright©2008 PR Newswire.
All rights reserved